

# Antonio Gasbarrini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5377448/publications.pdf>

Version: 2024-02-01

387  
papers

15,221  
citations

22153

59  
h-index

32842

100  
g-index

389  
all docs

389  
docs citations

389  
times ranked

20157  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.5	13
2	Correlation Between <i>QEIaXto</i> Techniques and Supersonic Imagine for Liver Stiffness Quantification in Chronic Liver Disease. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 877-886.	1.7	5
3	Role of gut microbiome on immunotherapy efficacy in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	3.3	12
4	Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1483-e1487.	4.4	4
5	Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. <i>European Radiology</i> , 2022, 32, 1320-1329.	4.5	5
6	Surveillance for hepatocellular carcinoma with a 3-months interval in extremely high-risk patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
7	Vitamin D and colorectal cancer: Chemopreventive perspectives through the gut microbiota and the immune system. <i>BioFactors</i> , 2022, 48, 285-293.	5.4	15
8	Diet-Induced Alterations in Gut Microbiota Composition and Function. , 2022, , .		1
9	The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorectal cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 649-656.	1.0	10
10	A metaproteomic-based gut microbiota profiling in children affected by autism spectrum disorders. <i>Journal of Proteomics</i> , 2022, 251, 104407.	2.4	14
11	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. <i>American Journal of Transplantation</i> , 2022, 22, 1191-1200.	4.7	29
12	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	4.4	20
13	Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 481.	3.7	13
14	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
15	Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. <i>Cancer Imaging</i> , 2022, 22, 1.	2.8	11
16	Food Additives, a Key Environmental Factor in the Development of IBD through Gut Dysbiosis. <i>Microorganisms</i> , 2022, 10, 167.	3.6	35
17	Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed). <i>Nutrients</i> , 2022, 14, 383.	4.1	12
18	Frailty Assessment in the Emergency Department for Patients ≥80 Years Undergoing Urgent Major Surgical Procedures. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 581-588.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Vaccines, Microbiota and Immunonutrition: Food for Thought. <i>Vaccines</i> , 2022, 10, 294.	4.4	9
20	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
21	Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients. <i>European Journal of Internal Medicine</i> , 2022, 101, 76-85.	2.2	6
22	Nutritional Support in Lung Cancer Patients: The State of the Art. <i>Clinical Lung Cancer</i> , 2021, 22, e584-e594.	2.6	11
23	Energy drinks: a narrative review of their physiological and pathological effects. <i>Internal Medicine Journal</i> , 2021, 51, 636-646.	0.8	14
24	Acute Diverticulitis in Elderly Patients: Does Age Really Matter?. <i>Digestive Diseases</i> , 2021, 39, 33-41.	1.9	10
25	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
26	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. <i>United European Gastroenterology Journal</i> , 2021, 9, 229-247.	3.8	66
27	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	1.3	37
28	Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNF± therapy. <i>Digestive and Liver Disease</i> , 2021, 53, 729-737.	0.9	11
29	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.9	6
30	European Registry on <i>Helicobacter pylori</i> management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. <i>United European Gastroenterology Journal</i> , 2021, 9, 38-46.	3.8	39
31	Autologous faecal microbiota transplantation for type 1 diabetes: a potential mindshift in therapeutic microbiome manipulation?. <i>Gut</i> , 2021, 70, 2-3.	12.1	45
32	The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 298-305.	0.9	37
33	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
34	Predicting In-Hospital Mortality in COVID-19 Older Patients with Specifically Developed Scores. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 37-43.	2.6	62
35	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. <i>Translational Research</i> , 2021, 231, 24-38.	5.0	21
36	Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 902-913.	1.9	5

#	ARTICLE	IF	CITATIONS
37	Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1569-1571.	5.7	6
38	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104.	3.1	3
39	COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12977.	2.7	17
40	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21%533 patients. <i>Gut</i> , 2021, 70, 40-54.	12.1	139
41	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
42	Anorectal Function and Quality of Life in IBD Patients With A Perianal Complaint. <i>Journal of Investigative Surgery</i> , 2021, 34, 547-553.	1.3	13
43	It's how we communicate! Exploring face-to-face versus electronic communication networks in multidisciplinary teams. <i>Health Care Management Review</i> , 2021, 46, 153-161.	1.4	8
44	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. <i>Journal of Viral Hepatitis</i> , 2021, 28, 651-656.	2.0	5
45	Profiling the Gastrointestinal Microbiota. <i>Methods in Molecular Biology</i> , 2021, 2283, 83-92.	0.9	3
46	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 599-622.	3.0	41
47	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. <i>PLoS ONE</i> , 2021, 16, e0245281.	2.5	25
48	Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1360-1361.	0.4	2
49	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
50	Management of acute cholecystitis in elderly patients: A propensity score-matched analysis of surgical vs. medical treatment. <i>Digestive and Liver Disease</i> , 2021, 53, 1620-1626.	0.9	9
51	Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). <i>Digestive and Liver Disease</i> , 2021, 53, 1451-1457.	0.9	6
52	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	3.2	34
53	Impact of Food Additive Titanium Dioxide on Gut Microbiota Composition, Microbiota-Associated Functions, and Gut Barrier: A Systematic Review of In Vivo Animal Studies. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2008.	2.6	17
54	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021, 13, 592.	3.7	5

#	ARTICLE	IF	CITATIONS
55	Gut and Reproductive Tract Microbiota Adaptation during Pregnancy: New Insights for Pregnancy-Related Complications and Therapy. <i>Microorganisms</i> , 2021, 9, 473.	3.6	23
56	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
57	Migraine as a Common Extra-Intestinal Presentation of Celiac Disease. , 2021, 5, .		0
58	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 853.	2.4	22
59	Early Procalcitonin Assessment in the Emergency Department in Patients with Intra-Abdominal Infection: An Excess or a Need?. <i>Surgical Infections</i> , 2021, 22, 787-796.	1.4	6
60	The gut microbiota and colorectal surgery outcomes: facts or hype? A narrative review. <i>BMC Surgery</i> , 2021, 21, 83.	1.3	31
61	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	1.8	8
62	Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2002.	4.1	27
63	Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. <i>Seminars in Oncology</i> , 2021, 48, 95-105.	2.2	11
64	Effect of influenza vaccine on COVID-19 mortality: a retrospective study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1849-1855.	2.0	56
65	The Role of Nutrition in the COVID-19 Pandemic. <i>Nutrients</i> , 2021, 13, 1093.	4.1	35
66	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
67	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. <i>Vaccines</i> , 2021, 9, 248.	4.4	0
68	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. <i>Nutrients</i> , 2021, 13, 960.	4.1	16
69	Advances in pharmacotherapeutics for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1343-1354.	1.8	5
70	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. <i>Nature Communications</i> , 2021, 12, 1926.	12.8	22
71	Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. <i>Liver International</i> , 2021, 41, 1320-1334.	3.9	51
72	The Healthy Gluten-Free Diet: Practical Tips to Prevent Metabolic Disorders and Nutritional Deficiencies in Celiac Patients. <i>Gastroenterology Insights</i> , 2021, 12, 166-182.	1.2	5

#	ARTICLE	IF	CITATIONS
73	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	2.0	37
74	Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. <i>Gastroenterology</i> , 2021, 160, 1891-1893.	1.3	6
75	Delta-Procalcitonin and Vitamin D Can Predict Mortality of Internal Medicine Patients with Microbiological Identified Sepsis. <i>Medicina (Lithuania)</i> , 2021, 57, 331.	2.0	6
76	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	8.1	5
77	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
78	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. <i>Journal of Personalized Medicine</i> , 2021, 11, 265.	2.5	14
79	Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1057-1060.	2.5	7
80	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	3.7	6
81	The role of elastography in non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 164-170.	0.5	7
82	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. <i>Digestive and Liver Disease</i> , 2021, 53, 1428-1432.	0.9	10
83	NutriCatt Protocol Improves Body Composition and Clinical Outcomes in Elderly Patients Undergoing Colorectal Surgery in ERAS Program: A Retrospective Cohort Study. <i>Nutrients</i> , 2021, 13, 1781.	4.1	3
84	Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2021, 53, 541-544.	0.9	1
85	Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population. <i>Cardiovascular Diabetology</i> , 2021, 20, 114.	6.8	12
86	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 2605.	2.4	12
87	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6485.	4.1	40
88	Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6711.	2.6	9
89	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. <i>Digestive and Liver Disease</i> , 2021, 53, 1527-1528.	0.9	0
90	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	5.0	35

#	ARTICLE	IF	CITATIONS
91	Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6242.	4.1	98
92	Dietary Habits and Gut Microbiota in Healthy Adults: Focusing on the Right Diet. A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6728.	4.1	19
93	Combination therapy in inflammatory bowel disease “ from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , 2021, 20, 102832.	5.8	34
94	Residual respiratory impairment after COVID-19 pneumonia. <i>BMC Pulmonary Medicine</i> , 2021, 21, 241.	2.0	23
95	Predictors of in-hospital mortality AND death RISK STRATIFICATION among COVID-19 PATIENTS aged ≥ 80 YEARS OLD. <i>Archives of Gerontology and Geriatrics</i> , 2021, 95, 104383.	3.0	33
96	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110258.	4.8	52
97	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2
98	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	3.7	15
99	Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2335-2343.	2.9	7
100	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. <i>CNS Drugs</i> , 2021, 35, 861-880.	5.9	29
101	Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. <i>Microorganisms</i> , 2021, 9, 1469.	3.6	6
102	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. <i>Nutrients</i> , 2021, 13, 2649.	4.1	24
103	Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients. <i>Gastroenterology</i> , 2021, 161, 368-369.	1.3	5
104	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100181.	5.6	43
105	Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions. <i>Frontiers in Immunology</i> , 2021, 12, 712915.	4.8	26
106	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 495-507.e4.	1.3	89
107	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 75, 1387-1396.	3.7	22
108	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.9	7



#	ARTICLE	IF	CITATIONS
109	Diet Intervention Study through Telemedicine Assistance for Systemic Nickel Allergy Syndrome Patients during the COVID-19 Pandemic. <i>Nutrients</i> , 2021, 13, 2897.	4.1	1
110	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	1.7	13
111	COVID-19, adaptative immune response and metabolic-associated liver disease. <i>Liver International</i> , 2021, 41, 2560-2577.	3.9	6
112	Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. <i>Hepatology</i> , 2021, 74, 1718-1718.	7.3	1
113	Antibiotic Resistance Prevalence and Trends in Patients Infected with <i>Helicobacter pylori</i> in the Period 2013-2020: Results of the European Registry on <i>H. pylori</i> Management (Hp-EuReg). <i>Antibiotics</i> , 2021, 10, 1058.	3.7	48
114	Frailty Assessment in the Emergency Department for Risk Stratification of COVID-19 Patients Aged ≥80 Years. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1845-1852.e1.	2.5	32
115	Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review. <i>Metabolites</i> , 2021, 11, 647.	2.9	5
116	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	3
117	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
118	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. <i>Breast</i> , 2021, 60, 6-14.	2.2	8
119	Development and Validation of Predictive Assessment of Complicated Diverticulitis Score. <i>Journal of Personalized Medicine</i> , 2021, 11, 80.	2.5	1
120	Bariatric procedures and microbiota: patient selection and outcome prediction. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2021, 14, 263177452110147.	1.9	0
121	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. <i>Italian Journal of Pediatrics</i> , 2021, 47, 18.	2.6	12
122	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1341-1356.	2.0	12
123	Gut Microbiota and Cardiovascular Diseases. <i>Cardiology in Review</i> , 2021, 29, 195-204.	1.4	22
124	Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , 2021, 13, 62.	3.4	10
125	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. <i>Scientific Reports</i> , 2021, 11, 21136.	3.3	14
126	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	2.8	4



#	ARTICLE	IF	CITATIONS
127	Incidence and Predictors of Thrombotic Complications in 4742 Patients with COVID-19 or Other Acute Infectious Respiratory Diseases: A Propensity Score-Matched Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4973.	2.4	3
128	Influence of Antihistamines on Basophil Activation Test in Food Allergy to Milk and Egg. <i>Diagnostics</i> , 2021, 11, 44.	2.6	1
129	Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review. <i>Atherosclerosis Plus</i> , 2021, 46, 1-14.	0.7	3
130	Fecal Microbiome Transplantation for Recurrent <i>Clostridioides difficile</i> Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 470-476.	0.9	3
131	Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. <i>World Journal of Hepatology</i> , 2021, 13, 1663-1676.	2.0	3
132	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	3.3	37
133	Dietary Magnesium Alleviates Experimental Murine Colitis through Modulation of Gut Microbiota. <i>Nutrients</i> , 2021, 13, 4188.	4.1	10
134	Humoral Predictors of Malignancy in IPMN: A Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12839.	4.1	12
135	Fecal microbiota transplantation for recurrent <i>C. difficile</i> infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. <i>Gut Microbes</i> , 2021, 13, 1994834.	9.8	21
136	Microbiota in Pancreatic Diseases: A Review of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 5920.	2.4	24
137	Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12836.	2.6	129
138	Factors Associated with ICU Admission in Patients with COVID-19: The GOL2DS Score. <i>Medicina (Lithuania)</i> , 2021, 57, 1356.	2.0	3
139	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. <i>World Journal of Gastroenterology</i> , 2021, 27, 8047-8057.	3.3	1
140	The Italian National Faecal Microbiota Transplantation Program: a coordinated effort against <i>Clostridioides difficile</i> infection. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2021, 57, 239-243.	0.4	1
141	Early oral vs parenteral nutrition in acute pancreatitis: a retrospective analysis of clinical outcomes and hospital costs from a tertiary care referral center. <i>Internal and Emergency Medicine</i> , 2020, 15, 613-619.	2.0	9
142	Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?. <i>Digestive Diseases</i> , 2020, 38, 204-210.	1.9	5
143	Anticoagulant therapy in the treatment of splanchnic vein thrombosis associated to acute pancreatitis: a 3-year single-centre experience. <i>Internal and Emergency Medicine</i> , 2020, 15, 1021-1029.	2.0	18
144	Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. <i>Nutrients</i> , 2020, 12, 65.	4.1	98

#	ARTICLE	IF	CITATIONS
145	Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19. <i>Internal Medicine Journal</i> , 2020, 50, 1483-1491.	0.8	19
146	Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1722-1724.	0.4	21
147	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , 2020, 12, 3101.	4.1	17
148	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154355.	3.4	23
149	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	3.7	9
150	Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features. <i>BMC Infectious Diseases</i> , 2020, 20, 775.	2.9	8
151	Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. <i>Digestive and Liver Disease</i> , 2020, 52, 1383-1389.	0.9	69
152	Make Mission Impossible Feasible: The Experience of a Multidisciplinary Team Providing Treatment for Alcohol Use Disorder to Homeless Individuals. <i>Alcohol and Alcoholism</i> , 2020, 55, 547-553.	1.6	6
153	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1063-1075.	8.1	35
154	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for <i>C. difficile</i> infection during the COVID-19 pandemic: A prospective cohort study. <i>Digestive and Liver Disease</i> , 2020, 52, 1390-1395.	0.9	16
155	Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020, 27, 100553.	7.1	66
156	Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. <i>British Journal of Haematology</i> , 2020, 191, 207-211.	2.5	84
157	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	3.3	36
158	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 857-865.	3.0	7
159	Wernicke's Encephalopathy in Alcohol Use Disorder Patients after Liver Transplantation: A Case Series and Review of Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 3809.	2.4	3
160	Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8816.	2.6	35
161	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.9	40
162	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1306-1314.	1.9	35

#	ARTICLE	IF	CITATIONS
163	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2103-2110.	2.6	7
164	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , 2020, 8, 1140.	3.6	35
165	“Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial” <i>Trials</i> , 2020, 21, 875.	1.6	6
166	Review: Extragastric diseases and <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2020, 25, e12741.	3.5	45
167	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. <i>RMD Open</i> , 2020, 6, e001171.	3.8	2
168	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 923-924.	3.7	7
169	Proteomics and Metabolomics Approaches towards a Functional Insight onto ALTISM Spectrum Disorders: Phenotype Stratification and Biomarker Discovery. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6274.	4.1	37
170	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. <i>Future Microbiology</i> , 2020, 15, 1173-1183.	2.0	18
171	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2020, 11, 4333.	12.8	82
172	Predicting intensive care unit admission and death for COVID-19 patients in the emergency department using early warning scores. <i>Resuscitation</i> , 2020, 156, 84-91.	3.0	94
173	Recent Insights on the Maternal Microbiota: Impact on Pregnancy Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 528202.	4.8	64
174	“Primum Non Nocere” in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications?. <i>Life</i> , 2020, 10, 180.	2.4	3
175	Diet and Nutrients in Gastrointestinal Chronic Diseases. <i>Nutrients</i> , 2020, 12, 2693.	4.1	34
176	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <i>Clinical Epigenetics</i> , 2020, 12, 126.	4.1	20
177	Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy. <i>Nutrients</i> , 2020, 12, 3277.	4.1	11
178	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096874.	3.2	4
179	The impact of personalized nutritional support on postoperative outcome within the enhanced recovery after surgery (ERAS) program for liver resections: results from the NutriCatt protocol. <i>Updates in Surgery</i> , 2020, 72, 681-691.	2.0	13
180	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of <i>Akkermansia muciniphila</i> . <i>Digestive and Liver Disease</i> , 2020, 52, 1002-1010.	0.9	23

#	ARTICLE	IF	CITATIONS
181	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. <i>United European Gastroenterology Journal</i> , 2020, 8, 353-354.	3.8	0
182	TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade. <i>Digestive and Liver Disease</i> , 2020, 52, 1188-1194.	0.9	15
183	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. <i>Journal of Clinical Medicine</i> , 2020, 9, 1757.	2.4	65
184	Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1699.	2.4	10
185	Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2358-2363.	3.8	96
186	Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic. <i>Journal of Ultrasound</i> , 2020, 23, 449-456.	1.3	29
187	Gut microbiome, big data and machine learning to promote precision medicine for cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 635-648.	17.8	172
188	Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <i>PLoS ONE</i> , 2020, 15, e0235359.	2.5	7
189	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	12.1	110
190	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068.	3.7	76
191	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 343-351.	3.1	29
192	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , 2020, 38, 522-533.	1.9	7
193	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , 2020, 40, 878-888.	3.9	68
194	Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms. <i>Digestive Endoscopy</i> , 2020, 32, 1031-1041.	2.3	35
195	A new ultrasound score for the assessment and follow-up of chronic pancreatitis: The "Gemelli USCP score"™. <i>Digestive and Liver Disease</i> , 2020, 52, 644-650.	0.9	4
196	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020, 73, 723.	3.7	2
197	Off-label use of tocilizumab in patients with SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2020, 92, 1787-1788.	5.0	102
198	Fecal calprotectin and need of multiple microbiota transplantation infusions in <i>Clostridium difficile</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1909-1915.	2.8	5

#	ARTICLE	IF	CITATIONS
199	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 339-343.	0.9	10
200	Endorotor-Based Endoscopic Necrosectomy as a Rescue or Primary Treatment of Complicated Walled-off Pancreatic Necrosis. A Case Series. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 681-684.	0.9	9
201	Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 151-157.	0.9	62
202	Resectable pancreatic solid lesions: Time to move from surgical diagnosis?. <i>Endoscopic Ultrasound</i> , 2020, 9, 76.	1.5	5
203	Letter: liver involvement and mortality in COVID-19 patients – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1264-1265.	3.7	3
204	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	3.7	249
205	Predictors of mortality of bloodstream infections among internal medicine patients: Mind the complexity of the septic population!. <i>European Journal of Internal Medicine</i> , 2019, 68, e22-e23.	2.2	4
206	Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 295-297.	1.5	2
207	Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , 2019, 9, 15373.	3.3	7
208	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 501.	4.1	39
209	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	3.2	47
210	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	3.9	41
211	A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection. <i>United European Gastroenterology Journal</i> , 2019, 7, 1051-1063.	3.8	35
212	Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 753-758.	2.4	7
213	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
214	Eosinophilic oesophagitis (in nickel-allergic patient) regressed after nickel oral desensitization: A case report. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841982777.	2.1	3
215	Impact evaluation of a Critical Pathway for patients with <i>Clostridium difficile</i> infection: A pre-post analysis in a Third Level Referral Center. <i>International Journal of Infectious Diseases</i> , 2019, 80, 105-110.	3.3	3
216	Wire-guided biliary cannulation: a comprehensive approach to a set of techniques. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1299-1305.	1.6	1

#	ARTICLE	IF	CITATIONS
217	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. <i>United European Gastroenterology Journal</i> , 2019, 7, 1408-1410.	3.8	15
218	ACE I allele is associated with more severe portal hypertension in patients with liver cirrhosis: A pilot study. <i>Digestive and Liver Disease</i> , 2019, 51, 293-296.	0.9	6
219	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI" San Marino study. <i>Digestive and Liver Disease</i> , 2019, 51, 218-225.	0.9	8
220	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	4.4	8
221	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.9	77
222	Management of celiac disease in daily clinical practice: do not forget depression!. <i>European Journal of Internal Medicine</i> , 2019, 62, e17.	2.2	3
223	Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , 2019, 22, 157-165.	1.3	16
224	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. <i>Computers in Biology and Medicine</i> , 2019, 104, 335-338.	7.0	3
225	Endoscopic Management of Benign Biliary Strictures After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 323-335.	2.4	36
226	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	7.3	433
227	Risk factors for gastric cancer: is it time to discard PPIs?. <i>Gut</i> , 2019, 68, 176-177.	12.1	14
228	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , 2019, 25, 4360-4382.	3.3	83
229	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , 2019, 25, 4437-4451.	3.3	47
230	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.	3.3	101
231	EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?. <i>Endoscopic Ultrasound</i> , 2019, 8, 220.	1.5	52
232	EUS: A one-stop shop approach for pancreatic head masses: Dream or reality?. <i>Endoscopic Ultrasound</i> , 2019, 8, 217.	1.5	1
233	Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. <i>Digestive Diseases</i> , 2018, 36, 184-193.	1.9	27
234	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.	3.1	6



#	ARTICLE	IF	CITATIONS
235	Performance of a new histology needle for EUS-guided fine needle biopsy: A retrospective multicenter study. <i>Digestive and Liver Disease</i> , 2018, 50, 469-474.	0.9	18
236	Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 451-456.	2.4	8
237	Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD). <i>Digestive and Liver Disease</i> , 2018, 50, 761-767.	0.9	23
238	NutriCatt protocol in the Enhanced Recovery After Surgery (ERAS) program for colorectal surgery: The nutritional support improves clinical and cost-effectiveness outcomes. <i>Nutrition</i> , 2018, 50, 74-81.	2.4	35
239	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	1.7	38
240	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 741-749.	0.9	24
241	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. <i>Digestive and Liver Disease</i> , 2018, 50, 421-428.	0.9	377
242	Non-specific gastrointestinal features: Could it be Fabry disease?. <i>Digestive and Liver Disease</i> , 2018, 50, 429-437.	0.9	28
243	Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. <i>Gynecologic Oncology</i> , 2018, 149, 263-269.	1.4	35
244	Faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2018, 67, 196.2-197.	12.1	18
245	Fecal calprotectin in management of <i>Clostridium difficile</i> infection: a longitudinal study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 567-572.	1.5	8
246	Alcohol addiction - the safety of available approved treatment options. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 169-177.	2.4	33
247	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	1.5	20
248	Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohn's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2921.	4.1	8
249	Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1941-1948.	1.8	17
250	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2313-2325.	2.4	29
251	Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1301-1311.	3.7	63
252	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9362-E9370.	7.1	110



#	ARTICLE	IF	CITATIONS
253	Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. <i>Frontiers in Psychiatry</i> , 2018, 9, 474.	2.6	19
254	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. <i>Clinical Epidemiology</i> , 2018, Volume 10, 203-213.	3.0	12
255	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 641-656.	3.0	95
256	Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. <i>Alcohol and Alcoholism</i> , 2018, 53, 151-156.	1.6	10
257	Risk, prevalence, and impact of hospital malnutrition in a Tertiary Care Referral University Hospital: a cross-sectional study. <i>Internal and Emergency Medicine</i> , 2018, 13, 689-697.	2.0	25
258	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 54-66.	4.4	34
259	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- $\alpha$ on the Liver. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2199.	4.1	62
260	Considering gut microbiota disturbance in the management of <i>Helicobacter pylori</i> infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 899-906.	3.0	12
261	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
262	Gut Microbiota Profiling and Gut-Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 675.	3.5	88
263	Wheat desensitization treatment in patients with gluten sensitivity. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 320-322.	0.9	2
264	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1232-1244.	3.8	137
265	The Use of Probiotics in Different Phases of Diverticular Disease. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 89-96.	0.8	25
266	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	3.9	10
267	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 751-759.	3.0	14
268	Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1493-1500.	2.0	6
269	Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. <i>Scientific Reports</i> , 2018, 8, 12624.	3.3	50
270	The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 925-929.	1.5	15

#	ARTICLE	IF	CITATIONS
271	Endoscopic Ultrasound for the Hepatologist: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2018, 38, 145-159.	3.6	5
272	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 543-551.	4.1	17
273	Forecasting Hepatitis C liver disease burden on real-life data. Does the 'hidden iceberg' matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
274	<i>Helicobacter pylori</i> in metabolic related diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2018, 64, 297-309.	2.2	11
275	EUS-guided fine-needle tissue acquisition for solid pancreatic lesions: Finally moving from fine-needle aspiration to fine-needle biopsy?. <i>Endoscopic Ultrasound</i> , 2018, 7, 137.	1.5	34
276	Performance of a new needle for endoscopic ultrasound-guided fine-needle biopsy in patients with pancreatic solid lesions: A retrospective multicenter study. <i>Endoscopic Ultrasound</i> , 2018, 7, 329.	1.5	36
277	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	12.1	793
278	Team work and cytopathology molecular diagnosis of solid pancreatic lesions. <i>Digestive Endoscopy</i> , 2017, 29, 657-666.	2.3	13
279	Watery stools and metabolic acidosis. <i>Internal and Emergency Medicine</i> , 2017, 12, 487-492.	2.0	2
280	Alcoholic cardiomyopathy: What is known and what is not known. <i>European Journal of Internal Medicine</i> , 2017, 43, 1-5.	2.2	74
281	Deep Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex in Alcohol Use Disorder Patients: Effects on Dopamine Transporter Availability and Alcohol Intake. <i>European Neuropsychopharmacology</i> , 2017, 27, 450-461.	0.7	62
282	Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. <i>Radiology</i> , 2017, 283, 820-827.	7.3	60
283	'Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017, 4, 69-73.	4.2	4
284	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	2.4	123
285	' <i>Helicobacter pylori</i> ' infection and extragastric diseases in 2017. <i>Helicobacter</i> , 2017, 22, e12411.	3.5	47
286	Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2017, 49, 1098-1103.	0.9	3
287	Transradial versus Transfemoral Access for Hepatic Chemoembolization: Inpatient Prospective Single-Center Study. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1234-1239.	0.5	44
288	ToF-SIMS and principal component analysis of lipids and amino acids from inflamed and dysplastic human colonic mucosa. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 6097-6111.	3.7	21

#	ARTICLE	IF	CITATIONS
289	Endoscopic necrosectomy through a lumen-apposing metal stent resulting in perforation: is it time to develop dedicated accessories?. <i>Endoscopy</i> , 2017, 50, 79-80.	1.8	4
290	Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2220-2222.	2.3	4
291	<i>Helicobacter pylori</i> infection contributes to placental impairment in preeclampsia: basic and clinical evidences. <i>Helicobacter</i> , 2017, 22, e12347.	3.5	20
292	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	1.3	10
293	Anti TNF- $\hat{\pm}$ therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	3.0	78
294	Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. <i>International Journal of Biological Markers</i> , 2017, 32, 397-402.	1.8	27
295	Can We Predict the Efficacy of Anti-TNF- $\hat{\pm}$ Agents?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1973.	4.1	73
296	<i>XRCC1</i> Arg399Gln Gene Polymorphism and Hepatocellular Carcinoma Risk in the Italian Population. <i>International Journal of Biological Markers</i> , 2017, 32, 190-194.	1.8	10
297	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2020.	4.1	53
298	Irritable Bowel Syndrome and Nickel Allergy: What Is the Role of the Low Nickel Diet?. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 101-108.	2.4	29
299	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-14.	1.4	16
300	Fecal microbiota transplantation: past, present and future perspectives. <i>Minerva Gastroenterology</i> , 2017, 63, 420-430.	0.5	22
301	The gut microbiota: its anatomy and physiology over a lifetime. <i>Minerva Gastroenterology</i> , 2017, 63, 329-336.	0.5	16
302	Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. <i>World Journal of Gastroenterology</i> , 2017, 23, 3195.	3.3	1
303	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.	2.0	50
304	How to modulate gut microbiota: diet, preprobiotics or antibiotics?. <i>Minerva Gastroenterology</i> , 2017, 63, 411-419.	0.5	1
305	May Gender or Ethnicity Affect Delta Over Baseline Values Obtained by 13-C Urea Breath Test?. <i>Reviews on Recent Clinical Trials</i> , 2017, 12, 187-192.	0.8	2
306	Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. <i>World Journal of Gastroenterology</i> , 2016, 22, 7186.	3.3	87

#	ARTICLE	IF	CITATIONS
307	Pancytopenia in a Patient with Rendu-Osler-Weber Syndrome and Uncommon Vascular Abnormalities. Case Reports in Hematology, 2016, 2016, 1-2.	0.4	1
308	Role and mechanisms of action of <i>Escherichia coli</i> Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology, 2016, 22, 5505.	3.3	141
309	Gut microbiota in autism and mood disorders. World Journal of Gastroenterology, 2016, 22, 361.	3.3	300
310	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	4.1	50
311	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver International, 2016, 36, 1033-1042.	3.9	28
312	Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 2016, 65, 1906-1915.	12.1	463
313	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases, 2016, 34, 269-278.	1.9	105
314	Human leukocyte antigen (HLA) DQ2/DQ8 prevalence in recurrent pregnancy loss women. Autoimmunity Reviews, 2016, 15, 638-643.	5.8	25
315	Gut Virome and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1708-1712.	1.9	39
316	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Applied and Environmental Microbiology, 2016, 82, 6633-6644.	3.1	85
317	High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. Expert Opinion on Pharmacotherapy, 2016, 17, 2135-2141.	1.8	17
318	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Digestive and Liver Disease, 2016, 48, 1043-1047.	0.9	6
319	New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors. Hypertension Research, 2016, 39, 868-873.	2.7	16
320	Gastroenterology training in Europe: unmet educational needs beyond the machines. Gut, 2016, 65, 185-187.	12.1	3
321	Eluxadolone for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 1395-1402.	1.8	10
322	Real-time diagnosis of <i>H. pylori</i> infection during endoscopy: Accuracy of an innovative tool (EndoFaster). United European Gastroenterology Journal, 2016, 4, 339-342.	3.8	16
323	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2016, 7, e139.	2.5	19
324	Bacillus clausii and gut homeostasis: state of the art and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	3.0	23

#	ARTICLE	IF	CITATIONS
325	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2016, 11, 3-10.	2.0	9
326	Diagnosis and treatment of small intestinal bacterial overgrowth. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 215-227.	3.0	40
327	Olmesartan-associated sprue-like enteropathy: know your enemy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 891-891.	1.5	1
328	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. <i>Digestive and Liver Disease</i> , 2016, 48, 391-398.	0.9	17
329	Enterography CT without and with water enema in patients with Crohn's disease: Results from a comparative observational study in comparison with endoscopy. <i>European Journal of Radiology</i> , 2016, 85, 404-413.	2.6	9
330	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	8.4	113
331	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 9727.	3.3	5
332	Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. <i>World Journal of Gastroenterology</i> , 2016, 22, 1935.	3.3	54
333	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1204-1213.	1.9	28
334	A case of granulocyte colony stimulating factor/plasmapheresis-induced activation of granulocyte colony stimulating factor-positive hepatic progenitors in acute-on-chronic liver failure. <i>Hepatology</i> , 2015, 62, 649-652.	7.3	14
335	Gastric Microbiota. <i>Helicobacter</i> , 2015, 20, 68-71.	3.5	68
336	Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. <i>Journal of Translational Medicine</i> , 2015, 13, 220.	4.4	10
337	Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 309.	2.3	81
338	The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	17
339	Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-5.	1.5	40
340	<i>Helicobacter pylori</i> and small intestinal bacterial overgrowth affect gastrointestinal symptoms in Fabry's disease. <i>Digestive and Liver Disease</i> , 2015, 47, 618-619.	0.9	5
341	Extragastric Diseases and <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2015, 20, 40-46.	3.5	150
342	Identification and Management of Alcohol Withdrawal Syndrome. <i>Drugs</i> , 2015, 75, 353-365.	10.9	127

#	ARTICLE	IF	CITATIONS
343	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 242-248.	0.9	53
344	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
345	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. <i>Journal of Hepatology</i> , 2015, 62, 191-212.		139
346	Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. <i>Computers in Biology and Medicine</i> , 2015, 65, 308-314.	7.0	11
347	Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, 351-355.	0.9	8
348	Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. <i>Current Cardiology Reports</i> , 2015, 17, 120.	2.9	125
349	Endometriosis and atherosclerosis: what we already know and what we have yet to discover. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 326-331.	1.3	20
350	The human gut microbiota and virome: Potential therapeutic implications. <i>Digestive and Liver Disease</i> , 2015, 47, 1007-1012.	0.9	226
351	Lactose intolerance genetic testing: Is it useful as routine screening? Results on 1426 south-central Italy patients. <i>Clinica Chimica Acta</i> , 2015, 439, 14-17.	1.1	20
352	Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 16, 179-185.	2.4	22
353	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , 2015, 21, 12322.	3.3	65
354	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1866.	2.0	24
355	Tumor Initiating Cells and Chemoresistance: Which Is the Best Strategy to Target Colon Cancer Stem Cells?. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	41
356	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 303.	1.9	19
357	Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 3173.	3.3	63
358	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2014, 93, e97.	1.0	77
359	The gastrointestinal microbiome – Functional interference between stomach and intestine. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 995-1002.	2.4	39
360	Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for "gut barrier protectors"™ in IBD?. <i>United European Gastroenterology Journal</i> , 2014, 2, 113-122.	3.8	31

#	ARTICLE	IF	CITATIONS
361	Acute refractory intestinal pseudo-obstruction in MELAS: Efficacy of prucalopride. <i>Neurology</i> , 2014, 82, 1932-1934.	1.1	13
362	Nutrients Affecting Gastric Barrier. <i>Digestive Diseases</i> , 2014, 32, 243-248.	1.9	15
363	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	43
364	Clinical effects of <i>Helicobacter pylori</i> outside the stomach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 234-242.	17.8	137
365	A pilot study of capsule endoscopy after a standard meal for the detection and grading of oesophageal varices in cirrhotic patients. <i>Digestive and Liver Disease</i> , 2014, 46, 997-1000.	0.9	2
366	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.	0.9	17
367	Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. <i>Human Reproduction Update</i> , 2014, 20, 582-593.	10.8	123
368	Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. <i>Transplantation Reviews</i> , 2014, 28, 92-101.	2.9	67
369	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 852-858.	1.3	54
370	Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. <i>Current Pharmaceutical Design</i> , 2014, 20, 4565-4569.	1.9	51
371	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. <i>World Journal of Gastroenterology</i> , 2014, 20, 8158.	3.3	17
372	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	2.8	218
373	Endoscopic tools for the diagnosis and evaluation of celiac disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 8562.	3.3	32
374	The Gut Barrier. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, S12-S17.	2.2	171
375	What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. <i>World Journal of Gastroenterology</i> , 2012, 18, 5014.	3.3	46
376	Intestinal Permeability in Cirrhotic Patients With and Without Spontaneous Bacterial Peritonitis: Is the Ring Closed?. <i>American Journal of Gastroenterology</i> , 2010, 105, 323-327.	0.4	110
377	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1479-1487.	1.8	12
378	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , 2009, 51, 682-689.	3.7	409



#	ARTICLE	IF	CITATIONS
379	Small Intestinal Bacterial Overgrowth: Diagnosis and Treatment. <i>Digestive Diseases</i> , 2007, 25, 237-240.	1.9	131
380	Rifaximin-Based Regimens for Eradication of <i>Helicobacter pylori</i> : A Pilot Study. <i>Digestive Diseases</i> , 2006, 24, 195-200.	1.9	25
381	Eradication of <i>Helicobacter pylori</i> : Are Rifaximin-Based Regimens Effective?. <i>Digestion</i> , 2006, 73, 129-135.	2.3	25
382	A Natural Diet Versus Modern Western Diets? A New Approach to Prevent "Well-Being Syndromes?". <i>Digestive Diseases and Sciences</i> , 2005, 50, 1-6.	2.3	20
383	Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 779-781.	1.0	29
384	<i>Helicobacter pylori</i> and Extragastric Diseases – Other <i>Helicobacters</i> . <i>Helicobacter</i> , 2004, 9, 57-66.	3.5	24
385	Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. <i>Gastrointestinal Endoscopy</i> , 2003, 57, 348-351.	1.0	64
386	Association of Virulent <i>Helicobacter pylori</i> Strains With Ischemic Heart Disease. <i>Circulation</i> , 1998, 97, 1675-1679.	1.6	299
387	Sarilumab Use in Severe SARS-CoV-2 Pneumonia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0